Faricimab

• EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPER-REFLECTIVE MATERIAL Recruiting
  2025-522701-38-00 Phase IV 1 country Asociacion Instituto De Investigacion Sanitaria Biobizkaia
• A phase IV study of Faricimab to explore associations of visual acuity benefits and changes in vascular integrity using adaptive optics in p… Recruiting
  2023-509829-52-00 Phase IV 1 country Martin-Luther-Universitaet Halle-Wittenberg
• A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasi… Recruiting
  2024-515640-22-00 Phase IV 3 countries Association For Innovation And Biomedical Research On Light And Image
• A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration Recruiting
  2024-517545-13-00 Phase III/IV 4 countries F. Hoffmann-La Roche AG
• Two initial faricimab loading doses in treatment-naive neovascular AMD Ended
  2024-514408-15-00 Phase IV 1 country Medical University Of Graz
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 Phase III 5 countries F. Hoffmann-La Roche AG
• Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked compar… Ended
  2024-515377-10-00 Phase III/IV 1 country Medical University Of Graz

Showing 1–7 of 7 trials